Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $153

BMO Capital analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $134 to $153.

byBenzinga Newsdesk

January 12, 2022

1 minute read

BMO Capital analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $134 to $153.

News

‘AVAV must discuss offensive not just defensive weapons with Mr. President’ – Tweet By Jim Cramer

By Benzinga Newsdesk

Today, 5:08 AM

https://twitter.com/jimcramer/status/1504448425890308101

AVAV

Stifel Maintains Buy on Roblox, Lowers Price Target to $90

By Benzinga Newsdesk

Today, 5:08 AM

Stifel analyst Drew Crum maintains Roblox (NYSE:RBLX) with a Buy and lowers the price target from $110 to $90.

RBLX

Recap: First Northwest Bancorp Q2 Earnings

By Benzinga Insights

Today, 5:08 AM

First Northwest Bancorp (NASDAQ:FNWB) reported its Q2 earnings results on Wednesday, January 26, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

FNWB

RBC Capital Maintains Outperform on Alimentation Couche-Tard, Raises Price Target to C$73

By Benzinga Newsdesk

Today, 5:08 AM

RBC Capital analyst Irene Nattel maintains Alimentation Couche-Tard (TSX:ATD) with a Outperform and raises the price target from C$65 to C$73.

TSX:ATD

BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $153

Related Posts

‘AVAV must discuss offensive not just defensive weapons with Mr. President’ – Tweet By Jim Cramer

Stifel Maintains Buy on Roblox, Lowers Price Target to $90

Recap: First Northwest Bancorp Q2 Earnings

RBC Capital Maintains Outperform on Alimentation Couche-Tard, Raises Price Target to C$73